Seattle Genetics reported earnings on Tuesday. Despite the solid growth in sales, shares opened down today, possibly due to conservative guidance for the year ahead. Adcetris sales in the U.S. and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. <a href="http://www.bizjournals.com/profiles/company/us/wa ...
* SEATTLE GENETICS - REQUIRED WAITING PERIOD UNDER HART-SCOTT-RODINO ACT REGARDING CO'S PROPOSED ACQUISITION OF CASCADIAN THERAPEUTICS EXPIRED ON FEB 15, 2018 Source text for Eikon: Further company ...
The FINANCIAL — Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited on October 28 announced that the companies have achieved completion of target patient enrollment in the phase 3 ECHELON ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results